entertainment -WSS

entertainment

author：entertainment 2025-09-01 15:17:55 - browse：323

JOSEPH PREZIOSO/AFP via Getty Images

Late-stage trial results for a pain medication developed by Vertex Pharmaceuticals reinforced experts’ sense that the drug was both safe and offered modest pain relief. But the findings also prompted fresh debate on Tuesday about how widely used the therapy would be should it win regulatory approval.

The company reported that its small molecule drug, VX-548, outperformed placebo in a pair of pain relief trials that recruited patients who had gotten an abdominoplasty (tummy tuck) or bunion surgery. The study also found that the drug was generally safe, with fewer patients on the medication reporting adverse events than those who had taken a placebo. But there was a catch: VX-548 didn’t outperform a combination of acetaminophen and the opioid hydrocodone, a key secondary endpoint. And in the bunionectomy study, the opioid comparator beat VX-548 on pain relief.

“While this study was not explicitly designed to test VX-548 vs. the opioid comparator, this may complicate the prescribing decision in the acute setting, where patients often take a short course of treatment and efficacy is a primary consideration,” Stifel market analyst Paul Matteis wrote in a note to investors, adding that results from three Phase 3 studies were positive overall.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： FDA panel signals lack of confidence in Amgen cancer drug data

hotspot

entertainment

WSS

Histogen: Failed biotech offers rare public look inside

STAT Event – Decoding Clinical Trials: Venture Capitalists Talk Early Biotech R&D

What to expect at HLTH 2023, the health care industry conference

STAT Event – Decoding Clinical Trials: Venture Capitalists Talk Early Biotech R&D

VC firm General Catalyst wants to buy a health system

After sickle

Wikipedia

entertainment

knowledge

Anesthesiologist group: stop taking Ozempic before surgery

Eli Lilly buys Point Biopharma in radiopharmaceuticals play

Activists slam private health insurers over coverage restrictions

FDA panel signals lack of confidence in Amgen cancer drug data

Dobbs anniversary: the lost opportunity of abortion as health care

CMS should re

George Santos makes 1st court appearance after pleading not guilty to 13 counts

CMS should re

Psychedelics group wrestles with new pharma identity

Was Amgen transparent enough on FDA's concern on cancer drug?

focus

AbbVie buys Immunogen, maker of targeted cancer drugs, for $10B

CMS should re

The woman behind the Dana Farber

Chemotherapy shortages won’t get better under Biden’s latest plan

VC firm General Catalyst wants to buy a health system

What to expect at HLTH 2023, the health care industry conference

entertainment

hotspot

entertainment

hotspot